NCT06194643Completed
Platelets in Pregnancy
Pregnancy Outcomes and Platelet PhenotYpes (POPPY)
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
This is a prospective observational cohort study of platelet phenotype in pregnant patients at high-risk for the development preeclampsia. Blood samples will be collected prior to the initiation of daily aspirin and again in the second trimester to evaluate for platelet changes during pregnancy in patient's as a result of aspirin use and their association with adverse perinatal outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 66 (actual)
- First submitted
- 22 Dec 2023
- Start date
- 17 Jan 2023
- Primary completion date
- 8 Jan 2025
- Lead sponsor
- NYU Langone Health
- Diseases
- High blood pressure
- NCT number
- NCT06194643
What you commit to
- Study type: Observational
- Participants enrolled: 66
- From 17 Jan 2023 to the primary completion date, 8 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antithrombotic or antiplatelet therapy
Other illness
- Allergy to aspirin
Lab values
- Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (Platelet count \<100,000), or thrombocytosis (Platelet count \>600)
Other
- Known hemorrhagic diathesis
- Planned delivery outside of NYU
Who the study is looking for
- Pregnant patients receiving prenatal care prior to 17 weeks at NYU Langone Health- Obstetrics \& Gynecology Associates
- Age 18-50 years
- Singleton viable gestation
- Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for low-dose aspirin (81 mg/day) prophylaxis for preeclampsia based on clinical risk factors (see below)
- Pregnant patients receiving prenatal care prior to 17 weeks at NYU Langone Health- Obstetrics \& Gynecology Associates
- Age 18-50 years
- Singleton viable gestation
- Pregnant patients at low risk of preeclampsia: Patients who do not meet USPSTF recommendation for low-dose aspirin (81 mg/day) prophylaxis for preeclampsia based on clinical risk factors.
Age in the registry: 18 years to 50 years · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.